Featured 13F manager
DAFNA Capital Management LLC Nathan Fischel
Los Angeles, CA 20 processed 13Fs on this site · 2021 Q3–2026 Q2
- $524M
- 88 Positions
- 2026 Q2
- +19.1% QoQ
- Top 5 40.2%
Nathan Fischel files DAFNA Capital Management LLC as a Form 13F. The latest book is 2026 Q2 at $524M, up 19.1% QoQ, led by Revolution Medicines, Spdr S&P Biotech ETF, and Compass Pathways.
Portfolio
top 5 40.2% · top 10 56.2%
- RVMD - Revolution Medicines 20.1%
- XBI - Spdr S&P Biotech ETF 5.9%
- CMPS - Compass Pathways 5.4%
- STXS - Stereotaxis 4.5%
- NKTR - Nektar Therapeutics 4.3%
- DNLI - Denali Therapeutics 3.6%
- IDYA - Ideaya Biosciences 3.5%
- ATRC - Atricure 3.2%
- XENE - Xenon Pharmaceuticals 2.9%
- CYTK - Cytokinetics 2.8%
- RCUS - Arcus Biosciences 2.6%
- ASND - Ascendis Pharma A/S 2.5%
- Other 38.7%
AUM over time
Book
| XBI - Spdr S&P Biotech ETF | 9.86% | Add +3.2% | 445,005 | $92.71 | $41M | +13,790 | +$338K |
| STXS - Stereotaxis | 5.95% | Hold | 13,680,554 | $1.82 | $25M | — | — |
| Merus | 5.79% | Add +8.0% | 409,445 | $59.17 | $24M | +30,450 | +$7M |
| CYTK - Cytokinetics | 5.15% | Hold | 398,100 | $54.18 | $22M | — | — |
| RVMD - Revolution Medicines | 4.75% | Hold | 511,894 | $38.81 | $20M | — | — |
| IDYA - Ideaya Biosciences | 3.54% | Reduce −5.4% | 422,213 | $35.11 | $15M | −24,128 | −$5M |
| ATRC - Atricure | 3.48% | Add +135.8% | 639,173 | $22.77 | $15M | +368,144 | +$6M |
| NDAQ - Ishares Nasdaq Biotech Indx | 3.36% | Hold | 102,500 | $137.26 | $14M | — | — |
| SNDX - Syndax Pharmaceuticals | 3.22% | Reduce −0.4% | 657,074 | $20.53 | $13M | −2,500 | −$2M |
| Blueprint Medicines | 2.70% | Reduce −1.9% | 104,763 | $107.78 | $11M | −2,000 | +$1M |
| ASND - Ascendis Pharma A/S | 2.64% | Reduce −12.4% | 80,972 | $136.38 | $11M | −11,500 | −$3M |
| XENE - Xenon Pharmaceuticals | 2.55% | Hold | 273,739 | $38.99 | $11M | — | — |
| VKTX - Viking Therapeutics | 2.40% | Reduce −2.6% | 189,117 | $53.01 | $10M | −5,000 | −$6M |
| NBIX - Neurocrine Biosciences | 2.36% | Hold | 71,615 | $137.67 | $10M | — | — |
| Kalvista Pharmaceuticals | 2.27% | Hold | 806,973 | $11.78 | $10M | — | — |
| DAWNGBX — | 2.19% | Hold | 666,463 | $13.78 | $9M | — | — |
| KURA - Kura Oncology | 2.08% | Add +2.6% | 423,500 | $20.59 | $9M | +10,837 | −$82K |
| TNDM - Tandem Diabetes Care | 1.97% | Reduce −20.9% | 204,208 | $40.29 | $8M | −54,000 | −$916K |
| Morphic | 1.89% | Hold | 231,748 | $34.07 | $8M | — | — |
| URGN - Urogen Pharma | 1.88% | New | 469,000 | $16.78 | $8M | +469,000 | +$8M |
| BHVN - Biohaven | 1.81% | Add +84.2% | 218,730 | $34.71 | $8M | +100,000 | +$1M |
| DXCM - Dexcom | 1.78% | Hold | 65,552 | $113.38 | $7M | — | — |
| AXGN - Axogen | 1.62% | Hold | 935,894 | $7.24 | $7M | — | — |
| EWTX - Edgewise Therapeutics | 1.25% | Reduce −5.2% | 290,197 | $18.01 | $5M | −16,000 | −$359K |
| LRMR - Larimar Therapeutics | 1.11% | Reduce −2.5% | 639,974 | $7.25 | $5M | −16,399 | −$342K |
| BCRX - Biocryst Pharmaceuticals | 1.04% | Reduce −0.7% | 704,500 | $6.18 | $4M | −5,000 | +$750K |
| IPSC - Century Therapeutics | 1.04% | Add +30.4% | 1,704,232 | $2.55 | $4M | +396,825 | −$1M |
| ALEC - Alector | 0.99% | Hold | 912,928 | $4.54 | $4M | — | — |
| 2seventy Bio | 0.97% | Reduce −12.7% | 1,050,709 | $3.85 | $4M | −153,342 | −$2M |
| RCUS - Arcus Biosciences | 0.92% | Add +9.3% | 253,217 | $15.23 | $4M | +21,500 | −$518K |
| LKFT - Galapagos | 0.77% | Hold | 130,175 | $24.78 | $3M | — | — |
| PODD - Insulet | 0.77% | Hold | 15,900 | $201.80 | $3M | — | — |
| Keros Therapeutics | 0.74% | Hold | 67,754 | $45.70 | $3M | — | — |
| Acelyrin | 0.73% | Add +242.4% | 693,609 | $4.41 | $3M | +491,022 | +$2M |
| ALKS - Alkermes | 0.69% | New | 120,700 | $24.10 | $3M | +120,700 | +$3M |
| STOK - Stoke Therapeutics | 0.67% | Add +43.1% | 207,427 | $13.51 | $3M | +62,427 | +$845K |
| CATBUSD - Astria Therapeutics | 0.60% | Add +22.8% | 274,165 | $9.10 | $2M | +50,900 | −$648K |
| BCYC - Bicycle Therapeutics | 0.59% | Hold | 122,200 | $20.24 | $2M | — | — |
| CATX - Perspective Therapeutics | 0.55% | New | 231,634 | $9.97 | $2M | +231,634 | +$2M |
| ARAY - Accuray | 0.53% | Hold | 1,222,358 | $1.82 | $2M | — | — |
| Iteos Therapeutics | 0.51% | Add +46.5% | 144,360 | $14.84 | $2M | +45,800 | +$798K |
| SPRY - Ars Pharmaceuticals | 0.49% | Hold | 239,194 | $8.51 | $2M | — | — |
| Mediwound | 0.46% | Reduce −34.1% | 124,479 | $15.52 | $2M | −64,274 | −$758K |
| BWAY - Brainsway | 0.43% | Hold | 297,655 | $6.07 | $2M | — | — |
| INGN - Inogen | 0.41% | Hold | 208,790 | $8.13 | $2M | — | — |
| Immatics | 0.40% | Hold | 145,000 | $11.62 | $2M | — | — |
| Regulus Therapeutics | 0.38% | Reduce −16.4% | 895,200 | $1.78 | $2M | −175,348 | −$1M |
| PRQR - Proqr Therapeutics | 0.36% | Hold | 905,582 | $1.66 | $2M | — | — |
| CMPS - Compass Pathways | 0.35% | Hold | 243,210 | $6.04 | $1M | — | — |
| ALLO - Allogene Therapeutics | 0.34% | New | 605,100 | $2.33 | $1M | +605,100 | +$1M |
| MLYS - Mineralys Therapeutics | 0.33% | Add +32.2% | 119,000 | $11.70 | $1M | +29,000 | +$230K |
| AQST - Aquestive Therapeutics | 0.33% | Add +6.0% | 530,000 | $2.60 | $1M | +30,000 | −$752K |
| Holding | 0.32% | Reduce −1.1% | 1,350,708 | $0.9973 | $1M | −15,600 | −$675K |
| ANRO - Alto Neuroscience | 0.31% | Add +1100.0% | 120,000 | $10.69 | $1M | +110,000 | +$1M |
| Gossamer Bio | 0.30% | Hold | 1,409,262 | $0.9009 | $1M | — | — |
| IMVT - Immunovant | 0.30% | Add +62.9% | 47,916 | $26.40 | $1M | +18,500 | +$315K |
| Sage Therapeutics | 0.30% | New | 116,200 | $10.86 | $1M | +116,200 | +$1M |
| AUTL - Autolus Therapeutics | 0.29% | Add +60.0% | 346,667 | $3.48 | $1M | +130,000 | −$176K |
| CNTA - Centessa Pharmaceuticals | 0.27% | New | 122,882 | $9.03 | $1M | +122,882 | +$1M |
| Tourmaline Bio | 0.23% | New | 75,982 | $12.86 | $977K | +75,982 | +$977K |
| Sutro Biopharma | 0.23% | Reduce −1.3% | 329,579 | $2.93 | $966K | −4,500 | −$922K |
| PRCT - Procept Biorobotics | 0.20% | Reduce −74.6% | 13,994 | $61.09 | $855K | −41,001 | −$2M |
| Polypid | 0.19% | Reduce −0.3% | 184,846 | $4.30 | $795K | −600 | −$58K |
| Compugen | 0.19% | Add +7.4% | 462,202 | $1.68 | $776K | +32,000 | −$333K |
| Nyxoah S A | 0.18% | New | 108,108 | $6.97 | $754K | +108,108 | +$754K |
| Adicet Bio | 0.17% | Hold | 600,000 | $1.21 | $726K | — | — |
| ACRV - Acrivon Therapeutics | 0.17% | Reduce −7.6% | 121,351 | $5.80 | $704K | −10,000 | −$235K |
| Syros Pharmaceuticals | 0.17% | Hold | 135,850 | $5.16 | $701K | — | — |
| ADCT - Adc Therapeutics SA | 0.15% | New | 204,081 | $3.16 | $645K | +204,081 | +$645K |
| TERN - Terns Pharmaceuticals | 0.14% | New | 86,000 | $6.81 | $586K | +86,000 | +$586K |
| Neuronetics | 0.13% | Hold | 313,717 | $1.80 | $565K | — | — |
| APRE - Aprea Therapeutics | 0.13% | Hold | 137,174 | $4.07 | $558K | — | — |
| NGNE - Neurogene | 0.10% | New | 11,000 | $36.39 | $400K | +11,000 | +$400K |
| Masimo | 0.09% | Hold | 3,000 | $125.94 | $378K | — | — |
| Adaptimmune Therapeutics | 0.08% | Hold | 341,064 | $0.9749 | $333K | — | — |
| ORIC - Oric Pharmaceuticals | 0.06% | New | 36,000 | $7.07 | $255K | +36,000 | +$255K |
| FHTX - Foghorn Therapeutics | 0.06% | New | 41,850 | $5.75 | $241K | +41,850 | +$241K |
| Nevro | 0.06% | Hold | 28,000 | $8.42 | $236K | — | — |
| GPCR - Structure Therapeutics | 0.05% | New | 5,000 | $39.27 | $196K | +5,000 | +$196K |
| Karyopharm Therapeutics | 0.04% | Hold | 192,678 | $0.8676 | $167K | — | — |
| Spero Therapeutics | 0.04% | Hold | 125,000 | $1.30 | $163K | — | — |
| CMPX - Compass Therapeutics | 0.03% | Hold | 116,882 | $1.00 | $117K | — | — |
Showing top 50 of 82 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2024 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Perspective Therapeutics | 0.84% | Exit | 0 | $1.19 | $4M | −3,103,644 | −$4M |
| BNTX - Biontech Se | 0.36% | Exit | 0 | $92.24 | $2M | −17,000 | −$2M |
| Vigil Neuroscience | 0.06% | Exit | 0 | $3.41 | $245K | −71,815 | −$245K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 88 | $524M | +19.1% | 13F-HR | 8/14/2026 | 000138993326000006 |
| 2026 Q1 | 83 | $440M | +2.1% | 13F-HR | 5/15/2026 | 000138993326000004 |
| 2025 Q4 | 77 | $431M | +6.4% | 13F-HR | 2/17/2026 | 000138993326000002 |
| 2025 Q3 | 75 | $405M | +11.9% | 13F-HR | 11/14/2025 | 000138993325000008 |
| 2025 Q2 | 76 | $362M | +2.5% | 13F-HR | 8/14/2025 | 000138993225000011 |
| 2025 Q1 | 83 | $353M | −10.2% | 13F-HR | 5/15/2025 | 000138993325000002 |
| 2024 Q4 | 82 | $393M | −7.1% | 13F-HR | 2/14/2025 | 000138993225000004 |
| 2024 Q3 | 84 | $423M | +1.0% | 13F-HR | 11/14/2024 | 000138993224000020 |
| 2024 Q2 | 83 | $419M | −4.6% | 13F-HR | 8/14/2024 | 000138993224000016 |
| 2024 Q1 | 72 | $439M | +5.3% | 13F-HR | 5/15/2024 | 000138993224000012 |
| 2023 Q4 | 76 | $417M | +29.9% | 13F-HR | 2/14/2024 | 000138993224000004 |
| 2023 Q3 | 75 | $321M | −12.3% | 13F-HR | 11/14/2023 | 000138993223000010 |
| 2023 Q2 | 73 | $366M | +9.6% | 13F-HR | 8/14/2023 | 000138993323000008 |
| 2023 Q1 | 72 | $334M | −5.9% | 13F-HR | 5/15/2023 | 000138993323000006 |
| 2022 Q4 | 79 | $355M | −4.6% | 13F-HR | 2/14/2023 | 000138993323000002 |
| 2022 Q3 | 87 | $372M | +1.4% | 13F-HR | 11/14/2022 | 000138993322000010 |
| 2022 Q2 | 90 | $367M | −4.4% | 13F-HR | 8/15/2022 | 000138993322000008 |
| 2022 Q1 | 94 | $384M | −3.5% | 13F-HR | 5/16/2022 | 000138993322000006 |
| 2021 Q4 | 87 | $398M | +5.6% | 13F-HR | 2/14/2022 | 000138993322000002 |
| 2021 Q3 | 80 | $377M | — | 13F-HR | 11/15/2021 | 000138993321000011 |
About
DAFNA Capital Management LLC
20 processed 13Fs on this site · 2021 Q3–2026 Q2